Security key
483497103
KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV)
CUSIP: 483497103
Q4 2017 13F Holders as of 31 Dec 2017
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 6,484,043
- Total 13F value
- $63,213,000
- Share change
- -1,231,248
- SEC-reported price per share
- $9.75
- Number of holders
- 23
- Value change
- -$2,998,314
- Number of buys
- 15
- Number of sells
- 7
- Shares outstanding
- 53,230,928
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2017
Institutions
23
Top holders
10
KALV full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2018
Previous quarter: Q3 2017
KalVista Pharmaceuticals, Inc. SEC filings
KalVista Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 483497103
Recent filing periods:
Ownership snapshot
Top reported holders of KALV - KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Novo Holdings A/S
Disclosed value leader
Novo Holdings A/S
Comparable rows
15/15
Latest evidence
30 Sep 2017
13F
Lead comparable stake: 5.1%
Showing 1-6 of 15 holder rows.
Quick read
Novo Holdings A/S leads the comparable SEC ownership view at 5.1%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Novo Holdings A/S's linked filing trail.
Comparable ownership
Top 5
Novo Holdings A/S
5.1%
SV Health Investors, LLC
4.8%
RA CAPITAL MANAGEMENT, L.P.
1.1%
EVENTIDE ASSET MANAGEMENT, LLC
0.74%
INTERWEST VENTURE MANAGEMENT CO
0.62%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Novo Holdings A/S |
13F
Company
|
5.1%
|
$18,341,000
2,725,283 shares
|
— | 30 Sep 2017 |
| SV Health Investors, LLC |
13F
Company
|
4.8%
|
$17,360,000
2,579,490 shares
|
— | 30 Sep 2017 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
1.1%
|
$4,350,000
591,070 shares
|
— | 30 Sep 2017 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
Company
|
0.74%
|
$2,637,000
396,000 shares
|
— | 30 Sep 2017 |
| INTERWEST VENTURE MANAGEMENT CO |
13F
Company
|
0.62%
|
$2,221,000
329,942 shares
|
— | 30 Sep 2017 |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC |
13F
Company
|
0.61%
|
$2,147,000
322,436 shares
|
— | 30 Sep 2017 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2017
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
23
Shares
6,484,043
Rows available
23
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2017 vs Q3 2017 Across Filers
Q3 2017 holders
15
Q4 2017 holders
23
Holder diff
8
| Investor | Q3 2017 Shares | Q4 2017 Shares | Share Diff | Share Chg % | Q3 2017 value | Q4 2017 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend